Theraclion obtains 8.5 Million euro in R&D funding
Printer Print Email Email
Paris: Theraclion, the only medtech company in the world developing an innovative technology for the treatment of hyperparathyroidism1,has announced that it has been granted 8.5 million euro in R&D funding by OSEO (the French state innovation agency) as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy. The ultrasound company SuperSonic Imagine will also participate in the Theraclion-driven project. The 8.5 million euro in funding comes as a direct, 3.5 million euro grant and 5 million euro in reimbursable advances. In all, 6.9 million euro of the total amount will be attributed to Theraclion, with 1.6 million pound going to SuperSonic Imagine. After 500,000 euro in 2005 and 1.3 million euro in 2007, this is the third time that OSEO has provided Theraclion with financial support. "We are proud to see that OSEO has given our company a vote of confidence by awarding significant funding for the third time running. We shall pursue our clinical trials (the interim results of which are very convincing) and prepare the forthcoming commercialization of our products. We are the only company in the world to use ultrasound and our "UNIS" method in the treatment of hyperparathyroidism and our strategy is also to explore new clinical applications to broaden our field of opportunities," says Ismael Nujurally, CEO, Theraclion.

Digital Supply Chain Transformation – Winning the AI/ML Way